Metformin and Weight Changes in Non-diabetic Older People With HIV (METFORAGING): A Double-Blind, Randomized, Placebo-Controlled, Pilot Trial.

Authors

Cristina Marcelo-Calvo, Andrés Esteban-Cantos, Francisco Jurado, Rocío Montejano, Lucía Gutiérrez-García, Alejandro de Gea-Grela, Patricia Martínez-Martín, Alejandro Díez-Vidal, Rosa de Miguel Buckley, Carlos M Oñoro-López, Juan C González, Luz Martín-Carbonero, José I Bernardino, Rocío Menéndez Colino, Noemí González Pérez de Villar, Berta Rodés, José R Arribas

Published in

Open forum infectious diseases. Volume 13. Issue 8. Pages ofag489. Epub Aug 06, 2026.

Abstract

Weight gain is a major complication of contemporary antiretroviral treatment (ART). We evaluated the effects of metformin on weight trajectories and metabolic outcomes in non-diabetic, non-obese, older persons with HIV-1 (PWH).
In this double-blind, randomized, placebo-controlled pilot trial (METFORAGING), PWH 50 years or older, virologically suppressed, without diabetes or insulin resistance, were randomly assigned (1:1) to metformin 850 mg or placebo twice daily for 96 weeks at La Paz University Hospital (Madrid, Spain). This prespecified secondary analysis evaluated changes in body weight, body mass index (BMI), glycemic indices, lipid parameters, and serum growth differentiation factor-15 (GDF-15) in the per-protocol population.
Forty participants were randomly assigned (metformin n = 19; placebo n = 21); 35 completed treatment through week 96 (per-protocol population). At week 96, mean weight change was -1.5 kg (95% CI -2.9 to -0.03) with metformin and +1.3 kg (-0.7 to 3.3) with placebo (between-group difference -2.8 kg [95% CI -5.2 to -0.4]; P = .025). After discontinuation, weight in the metformin group returned toward baseline (between-group difference from week 96 to 144: 2.2 kg [95% CI 0.05 to 4.5]; P = .045). At week 96, changes in body weight correlated inversely with changes in serum GDF-15 in the metformin group (r = -0.67; P = .003). No serious adverse events were attributed to metformin.
Metformin attenuated weight gain in nondiabetic, nonobese PWH receiving contemporary ART, but the effect was not sustained after discontinuation. These findings support larger trials to confirm efficacy and define optimal treatment duration.
EudraCT 2021-003299-15 (https://www.clinicaltrialsregister.eu).

PMID:
42609624
Bibliographic data and abstract were imported from PubMed on 18 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.